San Francisco, United States
Mekonos Inc. is a pioneering entity in the Biotechnology and Life Sciences sectors, with a unique foothold in Robotics and Semiconductor. The company, founded in 2017, is headquartered in the United States and holds a compelling vision articulated through its slogan, "Building the future of cell therapies on a chip."
Backed by Silicon Valley venture funds, Mekonos Inc. aims to revolutionize cell and gene therapies with its proprietary cell-engineering platform. This platform leverages scalable silicon technology, positioning the company as a catalyst in cell line development.
The company secured a substantial $25.00M Series A investment on 09 November 2021. This round was led by influential investors including Novartis, Sands Capital Ventures, and others like Debiopharm Innovation Fund, Elementum Ventures, and TDK Ventures. Such a diverse and robust investment portfolio underscores the company’s potential and strategic positioning in a rapidly evolving industry landscape.
